Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jan 2007

George Daniel J

Abstract excerpt

Frequent loss of the von Hippel-Lindau (VHL) gene product in conventional-type renal cell carcinoma results in constitutive expression of proangiogenic growth factors, including vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). VEGF and PDGF function in a paracrine manner to stimulate tumor angiogenesis that results in a hypervascular phenotype. Dependency on this...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Renal Cell
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imidazoles

Share to Indazoles

Share to Platelet-Derived Growth Factor

Share to Pyrroles

Share to Sunitinib

Share to Von Hippel-Lindau Tumor Suppressor Protein

Source

Identifiers

PMID: 17255305
DOI: 10.1158/1078-0432.CCR-06-2044

Genes

VHL

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase 2 studies of sunitinib and AG013736 in patients with cytokine-refractory renal cell carcinoma.PMID 17255305Read ↗

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.Semantic proximity Read ↗

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.Semantic proximity Read ↗

Pleiotropic stromal effects of vascular endothelial growth factor receptor 2 antibody therapy in renal cell carcinoma models.Semantic proximity Read ↗

Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.Semantic proximity Read ↗

Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma.Semantic proximity Read ↗

Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.Semantic proximity Read ↗

MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinomaSemantic proximity Read ↗

Molecular Pathways: Can Activin-like Kinase Pathway Inhibition Enhance the Limited Efficacy of VEGF Inhibitors?Semantic proximity Read ↗

Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.Semantic proximity Read ↗

Vascular Disruption in Combination with mTOR Inhibition in Renal Cell CarcinomaSemantic proximity Read ↗

Daily administration of low-dose daunorubicin or doxorubicin inhibits hypoxia-inducible factor 1 and tumor vascularizationSemantic proximity Read ↗

Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.